ViewRay reports Q4 EPS (15c), consensus (16c)

Reports Q4 revenue $34.7M, consensus $33.89M. ViewRay had total cash and cash equivalents of $142.5M at December 31, 2022. "Our innovation and clinical pipelines, along with increased market awareness efforts, are driving therapy adoption," said Scott Drake, CEO. "Over 29,000 patients have been treated to date, it’s clear that when patients know highly-effective, short-course, virtually side-effect-free therapy is available, they will demand it and travel for it. We focus on our mission of ‘Treating and proving what others can’t’ which position us to drive revenue growth, gross margin expansion, and expense leverage again in 2023."